Business & regional news

First ever FDA approval provides more options to meet patients’ personalized needs, including those with Parkinson’s disease

Deal expands Pain Interventions portfolio, now offering both unipedicular and bipedicular vertebral augmentation solutions

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.

Dr. Petrovski’s expertise will further strengthen Medtronic clinical and scientific activities to help people with diabetes live better with technology